PDF(Pubmed)
Abstract：
UNASSIGNED: To elucidate the incidence and treatment pattern of active exudative age-related macular degeneration (AMD).
UNASSIGNED: A population-based cohort study conducted using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a national claims database managed by the Japanese Ministry of Health, Labour, and Welfare (MHLW).
UNASSIGNED: The entire Japanese population aged 40 years or older (76 million people).
UNASSIGNED: With the permission of the MHLW, we accessed the complete NDB dataset and identified patients with newly diagnosed active exudative AMD between 2011 and 2018. The incidence of active exudative AMD was categorized by age and sex per year between 2011 and 2018; moreover, details regarding first-line therapy and number of anti-vascular endothelial growth factor (VEGF) injections per elapsed year since initial treatment were obtained and changes in treatment pattern were investigated.
UNASSIGNED: Incidence rate of active exudative AMD.
UNASSIGNED: During the specified 8-year period, 246 064 incident cases of active exudative AMD were identified; 61.4% of these patients were men. The overall incidence rate was 40.66 per 100 000 person-years (95% confidence interval [CI], 40.49-40.82) in the general population aged 40 years or older, 53.22 (95% CI, 52.95-53.49) in men, and 29.78 (95% CI, 29.60-29.98) in women. Mean age of onset was lower in men than in women (72.51 ± 10.50 years vs. 73.90 ± 10.46 years). Among patients with newly diagnosed active exudative AMD, 92.9% received anti-VEGF injections for initial treatments, whereas 1.8% underwent combination therapy with photodynamic therapy. The number of anti-VEGF injections in the first year (0-12 months), second year (13-24 months), and third year (25-36 months) after the initial injection was 3.66 ± 2.30, 1.39 ± 2.20, and 1.23 ± 2.19, respectively. Patients who received fewer injections in the first year received fewer injections in subsequent years and vice versa.
UNASSIGNED: This is a relatively large population-based study on the detailed epidemiology and actual treatment patterns of active exudative AMD in clinical practice. Our results can be a fundamental information source to ensure healthy eyes and promote well-being for all at all ages.
UNASSIGNED: A population-based cohort study conducted using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a national claims database managed by the Japanese Ministry of Health, Labour, and Welfare (MHLW).
UNASSIGNED: The entire Japanese population aged 40 years or older (76 million people).
UNASSIGNED: With the permission of the MHLW, we accessed the complete NDB dataset and identified patients with newly diagnosed active exudative AMD between 2011 and 2018. The incidence of active exudative AMD was categorized by age and sex per year between 2011 and 2018; moreover, details regarding first-line therapy and number of anti-vascular endothelial growth factor (VEGF) injections per elapsed year since initial treatment were obtained and changes in treatment pattern were investigated.
UNASSIGNED: Incidence rate of active exudative AMD.
UNASSIGNED: During the specified 8-year period, 246 064 incident cases of active exudative AMD were identified; 61.4% of these patients were men. The overall incidence rate was 40.66 per 100 000 person-years (95% confidence interval [CI], 40.49-40.82) in the general population aged 40 years or older, 53.22 (95% CI, 52.95-53.49) in men, and 29.78 (95% CI, 29.60-29.98) in women. Mean age of onset was lower in men than in women (72.51 ± 10.50 years vs. 73.90 ± 10.46 years). Among patients with newly diagnosed active exudative AMD, 92.9% received anti-VEGF injections for initial treatments, whereas 1.8% underwent combination therapy with photodynamic therapy. The number of anti-VEGF injections in the first year (0-12 months), second year (13-24 months), and third year (25-36 months) after the initial injection was 3.66 ± 2.30, 1.39 ± 2.20, and 1.23 ± 2.19, respectively. Patients who received fewer injections in the first year received fewer injections in subsequent years and vice versa.
UNASSIGNED: This is a relatively large population-based study on the detailed epidemiology and actual treatment patterns of active exudative AMD in clinical practice. Our results can be a fundamental information source to ensure healthy eyes and promote well-being for all at all ages.
摘要：
未经授权：阐明活动性渗出性年龄相关性黄斑变性（AMD）的发生率和治疗模式。
UNASSIGNED：使用日本国家健康保险索赔和特定健康检查数据库（NDB）进行的基于人群的队列研究，由日本卫生部管理的国家索赔数据库，劳工,和福利（MHLW）。
未经授权：日本总人口40岁或以上（7600万人）。
未经评估：经MHLW许可，我们访问了完整的NDB数据集,并确定了2011年至2018年间新诊断为活动性渗出性AMD的患者.在2011年至2018年之间，每年的活动性渗出性AMD的发病率按年龄和性别分类;此外，我们获得了有关一线治疗的详细信息和自初始治疗以来每一年注射抗血管内皮生长因子(VEGF)的次数,并研究了治疗模式的变化.
未经评估：活动性渗出性AMD的发病率。
未经评估：在指定的8年期间，发现246064例活动性渗出性AMD；这些患者中有61.4%是男性。总发病率为每10万人年40.66(95%置信区间[CI]，40.49-40.82）在40岁或以上的普通人群中，男性53.22（95%CI，52.95-53.49），女性为29.78（95%CI，29.60-29.98）。男性的平均发病年龄低于女性（72.51±10.50岁与73.90±10.46年）。在新诊断的活动性渗出性AMD患者中，92.9%接受抗VEGF注射进行初始治疗，1.8%接受了光动力疗法的联合治疗。第一年（0-12个月）的抗VEGF注射次数，第二年（13-24个月），首次注射后第3年（25-36个月）分别为3.66±2.30、1.39±2.20和1.23±2.19。在第一年接受较少注射的患者在随后的几年中接受较少注射，反之亦然。
UNASSIGNED：这是一项相对较大的基于人群的研究，涉及临床实践中活动性渗出性AMD的详细流行病学和实际治疗模式。我们的结果可以成为一个基本的信息来源，以确保健康的眼睛，促进所有年龄段的人的福祉。
UNASSIGNED：使用日本国家健康保险索赔和特定健康检查数据库（NDB）进行的基于人群的队列研究，由日本卫生部管理的国家索赔数据库，劳工,和福利（MHLW）。
未经授权：日本总人口40岁或以上（7600万人）。
未经评估：经MHLW许可，我们访问了完整的NDB数据集,并确定了2011年至2018年间新诊断为活动性渗出性AMD的患者.在2011年至2018年之间，每年的活动性渗出性AMD的发病率按年龄和性别分类;此外，我们获得了有关一线治疗的详细信息和自初始治疗以来每一年注射抗血管内皮生长因子(VEGF)的次数,并研究了治疗模式的变化.
未经评估：活动性渗出性AMD的发病率。
未经评估：在指定的8年期间，发现246064例活动性渗出性AMD；这些患者中有61.4%是男性。总发病率为每10万人年40.66(95%置信区间[CI]，40.49-40.82）在40岁或以上的普通人群中，男性53.22（95%CI，52.95-53.49），女性为29.78（95%CI，29.60-29.98）。男性的平均发病年龄低于女性（72.51±10.50岁与73.90±10.46年）。在新诊断的活动性渗出性AMD患者中，92.9%接受抗VEGF注射进行初始治疗，1.8%接受了光动力疗法的联合治疗。第一年（0-12个月）的抗VEGF注射次数，第二年（13-24个月），首次注射后第3年（25-36个月）分别为3.66±2.30、1.39±2.20和1.23±2.19。在第一年接受较少注射的患者在随后的几年中接受较少注射，反之亦然。
UNASSIGNED：这是一项相对较大的基于人群的研究，涉及临床实践中活动性渗出性AMD的详细流行病学和实际治疗模式。我们的结果可以成为一个基本的信息来源，以确保健康的眼睛，促进所有年龄段的人的福祉。
